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ABSTRACT
Objective: This study aimed to analyze the metformin hydrochloride in dried blood spot (DBS) sample and evaluate a pharmacokinetic profile in six 
healthy subjects who administered 850-mg metformin hydrochloride in tablet using high-performance liquid chromatography–photodiode array 
(HPLC–PDA).
Methods: Metformin analysis was performed on data of six healthy subjects who administered 850 mg of metformin hydrochloride as tablets. Blood 
samples were taken at 12-time points at intervals of up to 12 h, and data were analyzed using HPLC–PDA.
Results: A linear calibration curve was obtained in the range of 25–5000 ng/mL, with r=0.9990. Pharmacokinetic profiles of metformin were obtained 
using DBS samples from six healthy participants, with a Cmax of 347.3–416.22 ng/mL. The average tmax and t1/2 were obtained at 3 and 2 h, respectively, 
and the area under the curve (AUC)0-t/AUC0-∞ ratio was >80% for all subjects.
Conclusion: The DBS biosampling technique can be developed for application in pharmacokinetic study of metformin HCl.
Keywords: Dried blood spot, High-performance liquid chromatography, Metformin hydrochloride, Pharmacokinetic profile, Validation.
INTRODUCTION
Diabetes mellitus (DM) is a disorder of carbohydrate, protein, and fat 
metabolism due to decreased insulin secretion, insulin receptor sensitivity, 
or both and can be identified by hyperglycemia in the patient [1]. In 2015, 
the International Diabetes Federation rated Indonesia as the country with 
the seventh greatest number of people with diabetes aged 20–79 years, 
with 10 million people with the disease. By 2040, the number of people 
with diabetes in Indonesia is projected rise to 16.3 million. Furthermore, 
90–95% of all cases of diabetes are type 2 DM [2].
Metformin is the first-line medication for patients with type 2 DM and 
is the drug of choice for type 2 DM patients with obesity [3]. Metformin 
is included in the National List of Essential Medicines, the list of drugs 
that are assessed using a bioequivalence (BE) test, and was one of the 
most commonly prescribed drugs worldwide in 2014 [4-8].
Pharmacokinetic studies comprise a series of tests to determine the 
pharmacokinetic parameters of a drug [4]. They generally use plasma 
samples, and biosampling techniques are performed by taking a 
volume of approximately 5–15 mL of blood through venipuncture, 
often causing discomfort for the subject. However, over the past 
5–7 years, a dried blood spot (DBS) technique has been intensively 
developed and evaluated for the quantification of drug exposure 
in non-clinical as well as clinical studies at various phases for 
drug research and development. DBS is an innovative biosampling 
technique in which small quantities (10–80 μL) of wet blood samples 
are collected on DBS paper or other paper materials then dried for 
2–3 h at room temperature or under nitrogen gas flow with controlled 
air humidity [9]. This method is preferable as it is minimally invasive 
for the patient (using a sterile lancet), the volume of blood required 
is low, it is simple and does not cost much to implement, and the 
analytes in the dry blood sample are relatively stable in the long term. 
Metformin is reported to be partitioned into erythrocytes; therefore, 
the use of DBS could be considered instead of plasma samples to 
measure metformin concentrations [10,11].
Metformin hydrochloride analysis using DBS samples requires a device 
that has high selectivity and sensitivity due to the low blood volume 
and the fact it is derived from the periphery [12]. High-performance 
liquid chromatography (HPLC) is the most widely used technique for 
drug analysis in biological matrices. It is a commonly used instrument 
that is available in the laboratory and analytical methods are more 
applicable [13]. Photodiode array (PDA) detectors are commonly used 
and are advantageous in sensitive and selective HPLC systems for the 
analysis of drugs and their metabolites in biological matrices [14].
To date, there have been no reports of pharmacokinetic tests of metformin 
hydrochloride using the DBS biosampling technique. Further, analysis is 
required to determine whether metformin hydrochloride bioanalysis using 
the DBS biosampling technique can be applied in vivo as well as more widely.
In the present study, six healthy subjects administered 850 mg of 
metformin hydrochloride in tablet formulation. Blood samples were taken 
at 12-time points at various intervals up to 12 h. The study was approved 
Ethical Clearance from the Medical Research Ethics Committee of the 
Faculty of Medicine, Universitas Indonesia (no. 63/UN2.FI/ETIK/2017).
The aim of the present study was to the analyze metformin hydrochloride 
in DBS sample and evaluate a pharmacokinetic profile in six healthy 




HPLC (Waters 2695 Separation Mode) consisting of pumps, an 
autosampler, C18 column (Waters, SunfireTM 5 μm; 250×4.6 mm), 
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PDA (Waters 2996), and a computer for data processing. Other 
equipment used included a pH meter (Eutech pH 510), evaporator 
(Turbovap Caliper), analytical scales (Acculab), eluent filters and 
samples (Whatman), degasser (Elmasonic S60H), vortex (Maxi Mix II), 




DBS samples were obtained from blood samples collected on DBS 
paper from six healthy subjects who administered 850 mg of metformin 
hydrochloride in tablet.
Chemical materials
The materials used included metformin hydrochloride and calcium 
atorvastatin were purchased from British Pharmacopoeia, HPLC grade 
acetonitrile (Merck), HPLC grade methanol (Merck), sodium dihydrogen 
phosphate monohydrate (Merck), sodium dodecyl sulfate (SDS) (SDS; 
Merck), orthophosphoric acid (Merck), sodium hydroxide (NaOH) 
(NaOH; Merck), aquabidest (Ikapharmindo), DBS paper (Perkin Elmer), 
human blood (Indonesian Red Cross), and 850-mg immediate release 
metformin hydrochloride tablets (Merck).
Sampling materials
Sampling materials included sterile pens and lancets (sterile needle; 
Medilance), Eppendorf micropipettes (Socorex), alcohol swabs 
(OneMed), and 0.5-mL vacutainers (GM Micro Tube).
Stock solution of metformin HCl and atorvastatin
10 milligrams of standard metformin hydrochloride were carefully 
weighed and added into a 10-mL measuring flask. The substance was 
dissolved in aquabidest, to a final volume of 10 mL, giving a standard 
compound solution of 1000 μg/mL. The stock solution was diluted 
to obtain solutions of various concentrations for a calibration curve. 
10 mg of standard atorvastatin compound were also carefully weighed 
and dissolved with methanol to a final volume of 10 mL. The resulting 
stock solution of 1000 μg/mL was diluted to obtain solutions of various 
concentrations.
Chromatography conditions
HPLC–PDA was performed using a detector with a wavelength of 
234 nm. The column used was a C18 (Waters, SunfireTM 5 μm; 
250×4.6 mm). The mobile phase was 10-mM SDS and 10-mM phosphate 
buffer in water-acetonitrile (60:40) and then was adjusted to pH 7.0 
with orthophosphoric acid and NaOH; the column temperature was 
40°C; flow rate was 0.8 mL/min, with an analysis time of 10 min.
Sample preparation
A volume of 20 μL of blood containing analytes was pipetted and spotted 
on DBS paper. The samples were then dried at room temperature 
(20–25°C) for 3 h. After drying, the paper was cut according to the 
marking on the paper, then inserted into a microtube, and 50 μL of 
atorvastatin (10 μg/mL) as an internal standard and 0.5 mL of methanol 
(60%) as the extracting solvent were added. Sonication was performed 
for 10 min. The process was continued by mixing the solution using a 
vortex for 90 s. The solution was then transferred into the microtubes 
and evaporated to dryness at 60°C for 15 min under nitrogen gas. The 
residue was reconstituted by adding 200 μL of mobile phase followed by 
sonication for 3 min. The solution was then transferred to an autosampler 
vial and centrifuged for 10 min (room temperature, 3000 rpm, 10 min). 
A 100-μL sample volume was injected into HPLC system.
Partial validation of bioanalysis methods
Calibration curve and linearity test
Blank samples (whole blood without analyte), zero samples (whole 
blood with internal standard), and metformin hydrochloride solution in 
whole blood at concentrations of 25, 50, 75, 100, 500, 1000, 2500, 3750, 
and 5000 ng/mL were collected. A calibration curve was obtained by 
spiking each blood sample to obtain the desired concentration. Then, 
20 μL of the spiked blood was collected on DBS paper and dried for 
around 3 h. The paper was cut according to the marking on the paper and 
inserted into microtubes. Next, 50 μL of atorvastatin (10 μg/mL) was 
added as an internal standard and extracted using the same extraction 
method as used for the sample preparation. A 100-μL sample volume 
was injected into the HPLC system.
The regression value of the peak area (y) to the concentration of analyte 
in plasma (x) was calculated for each concentration, and a calibration 
curve was prepared. A linearity test was performed using data from 
the calibration curve, then analyzed using peak area regression to 
the metformin concentration in the DBS sample, and a correlation 
coefficient (r) was obtained, demonstrating its linearity. In addition, 
calculation of the percentage difference (% diff) with the limit value of 
% diff did not exceed 20% for the lower limit of quantification (LLOQ) 
and 15% for all other concentrations.
Within-run accuracy and precision
Metformin hydrochloride solutions in whole blood were made with 
LLOQ concentration and metformin quality control (QC) solutions 
with low, medium, and high (QC low [QCL], QC medium [QCM], and QC 
high [QCH], respectively) concentrations. A volume of 20 μL of blood 
was spotted on DBS paper, dried for around 3 h, and the paper was cut 
according to the marking on the paper. The paper was inserted into 
microtubes, then 50 μL of atorvastatin (1 μg/mL) was added as an 
internal standard and extracted using the same method as the sample 
preparation. Next, a 100-μL sample volume was injected into HPLC 
system. Accuracy and precision tests were performed using five replicas 
at each concentration in one run (intrabatch/within-run accuracy). 
The % diff of data obtained was calculated to determine the accuracy. 
The precision was measured using the calculation of the coefficient 
of variation (% CV) data obtained. The requirement % diff and % CV 
values were <20% for LLOQ and <15% for all other concentrations.
Treatment of healthy subjects
The scope of the study was explained to the six healthy subjects, and 
all gave signed informed consent and passed the screening. The day 
before the sampling, the subjects quarantined at the Bioavailability 
and Bioequivalence Laboratory of the Faculty of Pharmacy, Universitas 
Indonesia. After an 8-h fast, each subject received an oral dose of 
850-mg metformin hydrochloride tablets, with 240 mL of water. To 
prevent hypoglycemia, subjects were given 100 mL of a 10% glucose 
solution every hour for 3 h. Subsequently, at 4, 8, and 12 h after 
administration of the 850-mg metformin hydrochloride tablet, subjects 
were fed standard foods. Standardization of body position and physical 
activity throughout the study day was ensured due to their effects on 
motility and blood flow of the gastrointestinal tract.
Sampling and preparation of DBS samples from healthy subjects
Blood samples were taken at 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 
8, and 12 h after administration of 850-mg metformin hydrochloride 
tablets in six healthy subjects (12-point collection). Blood collection 
was performed through finger prick using a sterile lancet needle. The 
amount of blood used for this study was approximately 40 μL. Blood 
was collected in 0.5-mL vacutainers, and 20 μL was spotted on DBS 
paper and dried for approximately 3 h. The paper was cut out according 
to the marking on the paper, inserted into microtubes.
Metformin hydrochloride analysis in the sample
Analysis was performed using HPLC–PDA (100-μL sample injection 
volume) with an optimized mobile phase to determine the concentration 
of metformin hydrochloride in healthy subjects who administered 850-
mg metformin hydrochloride in tablet to evaluate the pharmacokinetic 
profile. From the peak area obtained, the concentration of metformin 
hydrochloride was calculated using a standard calibration curve.
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Calculation of pharmacokinetic parameters
Metformin hydrochloride blood concentration data were plotted to form 
a pharmacokinetic profile curve (concentration vs. time). From these 
data, the pharmacokinetic parameters of the maximum concentration 
in blood (Cmax) and the maximum time (tmax) were calculated. Other 
pharmacokinetic parameters determined included half-life (t½), area 
under the curve (AUC)0-t, and AUC0-∞.
RESULTS AND DISCUSSION
Calibration curves
The results indicated that the range of the calibration curve for metformin 
was 25–5000 ng/mL. The calibration curve consisted of blanks (whole 
blood without analyte and internal standard), zero samples (whole 
blood with internal standard), and non-zero blood (whole blood with 
analyte and internal standard) using nine different concentrations: 25, 
50, 75, 100, 500, 1000, 2500, 3750, and 5000 ng/mL. The calibration 
curve yielded a linear regression equation of y=0.0003x+0.0114 
with r=0.9990, where x represents the concentration of metformin 
(ng/mL) and y represents the peak area ratio between metformin and 
atorvastatin. These data show that the calibration curve obtained met 
the requirements of ≤20% at concentrations of LLOQ and ≤15% at 
other concentrations.
Within-run accuracy and precision
In the present study, only partial validation was performed, including 
precision and intraday accuracy. According to the 2011 guideline of 
Bioanalytical Method Validation from the EMEA, partial validation can 
be performed, starting with intraday accuracy and precision parameters 
until almost all validation parameters are full. Full validation was not 
performed because the analytical methods were fully validated in 
other studies using the same research conditions including location, 
instruments, methods of extraction, and bioanalysis methods. An 
accuracy test was performed to assess the similarity between the 
measured and actual concentrations by determining its bias value 
(% diff). A precision test was conducted to determine the proximity of 
the repetition of the measurement analytes by analyzing the value of  % 
CV. The accuracy and precision tests were performed using five replicas 
of four different concentrations of metformin hydrochloride in whole 
blood, namely LLOQ, QCL, QCM, and QCH. It was essential that both 
accuracy and precision met the requirement stated in the guidelines by 
the EMEA, that is, ≤20% at concentrations of LLOQ and ≤15% at other 
concentrations.
The results of the within-run accuracy testing on metformin met the 
requirements; the % diff value at LLOQ concentration was 12.35%–
17.43%, and the QC concentration was 1.48–13.60%. The within-run 
precision test also met the requirements for the analyte with a % CV 
value for metformin at 2.79% for LLOQ, 2.75% for QCL, 1.56% for 
QCM, and 2.37% for QCH. Although the obtained % CV and % diff were 
different from previous studies, the accuracy and precision test results 
in the analytes remained within the required range, and still qualified, 
demonstrating that the method of analysis was accurate and precise.
Analysis of samples from healthy subjects
Sampling process
Blood samples were taken under the supervision of a doctor. 
The subjects then received an oral dose of 850-mg metformin 
hydrochloride in tablet (Glucophage) with 240 mL of water. To prevent 
hypoglycemia, subjects were given 100 mL of a 10% glucose solution 
every hour for 3 h. Subsequently, at 4, 8, and 12 h after administration 
of metformin hydrochloride, the subjects were fed standard meals. 
Body position and physical activity were standardized throughout 
the study day due to their effects on motility and blood flow of the 
gastrointestinal tract.
Up to 40 μL of blood was collected at 12-time points: 0 (predose), 0.5, 
1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 12 h after administration of 850-mg 
metformin hydrochloride tablets. Blood collection was performed 
through finger prick using a sterile lancet needle. The collected blood 
was then transferred to 0.5-mL vacutainers. Side effects were monitored 
during the study based on direct questions, spontaneous reports, and 
clinical parameters measured during the sampling process. Adverse 
event during the sampling process or complaints from the subject were 
monitored and studied by the doctor.
After blood was collected, 20 μL was directly spotted on DBS paper 
and dried in a horizontal position for 3 h in an open space at room 
temperature (20–25°C). Samples were stored in an airtight plastic 
(sealable plastic) with a silica pack to control the moisture during 
storage. Humidity was well controlled to reduce the risk of analytical 
degradation due to bacterial growth that may have affected the 
results of the analysis. The dried blood samples were stored at room 
temperature in dry and cool (20–25°C) conditions before analysis. The 
DBS sample was then prepared for partial validation methods.
Sample analysis results
Analysis was performed on one batch to generate three calibration 
curves (CC1, CC2, and CC3). Sample QC 1 consisted of QCL, QCM, and 
QCH of each of two replicas, and 12 sample points of subject 1; sample 
QC 2 consisted of QCL, QCM, and QCH of each of two replicas, 12 sample 
points of participant 2; and sample QC 3 consisted of QCM and QCH 
of each of the two replicas. The calibration curve yielded a linear 
regression equation of y=0.0003x+0.0116, with r=0.9980 for CC1; 
y=0.0003x+0.0119, with r=0.9990 for CC2; and y=0.0003x+0.0112, 
with r=0.9992 for CC3. Sample analysis was completed within 1 month 
after sampling. The analysis time still met the requirements as the long-
term stability validation was 45 days.
Fig. 1 shows the metformin hydrochloride concentrations in blood 
plotted on a pharmacokinetic profile curve (concentration vs. time). The 
data show the pharmacokinetic parameters, that is, AUC, the maximum 
concentration in blood (Cmax), maximum time (tmax), and halftime (t½). 
The calculated pharmacokinetic parameters for each participant are 
shown in Table 1.
The results showed that the Cmax obtained from six healthy 
subjects ranged from 347.3 to 416.22 ng/mL. The mean Cmax was 
367 ng/mL with a standard deviation of 26.14 ng/mL. The lowest 
Cmax concentration was 347.3 ng/mL, observed in subject CF1, and the 
highest concentration was 416.22 ng/mL, observed in subject CF4. 
There was a slight difference in the maximum concentration measured 
in each participant. This was due to variations in the body’s response 
to metformin and metabolic processes occurring in each participant, 
resulting in variations in concentrations. The tmax in the six test subjects 
was observed at the sixth and seventh blood sampling time points, 
that is, at 2.5 h after drug administration for subjects CF1, CF2, CF4, 
and CF5 and 3 h after drug administration for subjects CF3 and CF6. 
The mean tmax for the six subjects was 3 h. This was in accordance with 
the literature showing that tmax was obtained around 2–3 h after drug 
Fig. 1: Mean pharmacokinetic profile versus time of metformin 
HCL on six healthy subjects in dried blood spot samples
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administration [15]. Our results showed that the AUC0-t/AUC0-∞ met the 
requirements of >80% for all test subjects.
The Cmax values obtained from the six subjects showed that the achieved 
LLOQ was in the range of 6.00–7.10% of the maximum concentration 
of the analyte in the body (Cmax), while the EMEA requirement is 5%. 
As there were no previous studies on the pharmacokinetic profile of 
metformin hydrochloride with biosampling of DBS, the concentration 
of metformin in plasma was used as a reference for Cmax. However, we 
demonstrated that the Cmax for metformin using DBS was lower than 
the Cmax for metformin in plasma; therefore, a more sensitive LLOQ 
was required in the range of 17.4–20.91 ng/mL. This could have been 
caused by unextracted analytes in the DBS paper, making the LLOQ 
measurements less sensitive. The DBS paper used was polar and made 
of cellulose, so there was a high probability of metformin having polar 
properties, strongly bound to the DBS paper.
The metformin concentrations in DBS were lower than those in plasma. 
Following administration of 850-mg metformin hydrochloride tablets, 
the Cmax of metformin in plasma was 1000–1500 ng/mL (Porta et al., 
2008). A major contributor to the lower concentration of metformin in 
DBS samples compared with plasma is due to the blood samples being 
taken from the periphery and in small volumes. Whole blood from the 
periphery comprises blood cells, plasma, and interstitial fluid, as well 
as more intrusive components. In addition, there was a difference in 
analyte concentration in the periphery (capillary vessels) with the 
veins [12,16]. The distribution coefficient (cP/cBC) for metformin was 
4.65±0.73. This suggests that the plasma concentration of metformin is 
4 times higher than that of the blood cell concentration [11]. This may 
have contributed to the lower concentration of metformin observed 
with DBS biosampling compared with venous biosampling. Therefore, a 
multiplier factor is required to convert the concentration from the DBS 
analyzer to the plasma analyzer concentration.
The DBS method has more advantages than vein biosampling method. It 
is a more comfortable method of biosampling as it is minimally invasive, 
especially during the pharmacokinetic and BE tests, where blood were 
collected for several points (12-18 times) over a period of time. The 
technique is also simpler and does not cost much to implement, and 
the analytes in the sample tend to be more stable compared with other 
biosampling techniques [11]. Metformin is partitioned in erythrocytes; 
therefore, DBS biosampling for metformin analysis is possible and can 
be used for pharmacokinetic, BE, or other metformin clinical trials. 
This method has been demonstrated to meet the validation criteria and 
can be applied in vivo. However, future studies are required to develop 
further methods of extraction to improve the recovery so to achieve 
LLOQ analysis.
CONCLUSION
The DBS biosampling technique can be developed for application in 
pharmacokinetic study of metformin HCl.
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Table 1: Results of pharmacokinetic parameters
Subject Cmax (ng/mL) tmax (h) t½ (h) AUC0–t (ng.h/mL) AUC0–∞ (ng.h/mL) AUC0–t/ AUC0–∞ (%)
CF1 347.3 2.5 1.67 1309.36 1309.36 100
CF2 348.4 2.5 1.67 1349.87 1349.87 100
CF3 362.94 3 2.80 1729.3 1833.51 94.32
CF4 416.22 2.5 2.94 1861.79 1968.31 94.59
CF5 352.64 2.5 1.65 1404.53 1404.53 100
CF6 373.02 3 2.48 1772.04 1861.68 95.18
Mean±SD 367±26.14 3±0.26 2±0.61 1571±242.94 1621±297.05 97.35±2.92
% CV 7.13 9.68 27.63 15.46 18.32 3.00
% CV: Coefficient of variation, SD: Standard deviation, AUC: Area under the curve 
